Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Net Cash Flow (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Net Cash Flow for 15 consecutive years, with -$2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 119.94% year-over-year to -$2.0 million, compared with a TTM value of -$1.3 million through Sep 2025, down 113.32%, and an annual FY2024 reading of $10.7 million, up 381.52% over the prior year.
  • Net Cash Flow was -$2.0 million for Q3 2025 at Sanara MedTech, up from -$3.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $26.9 million in Q1 2021 and bottomed at -$3.7 million in Q2 2025.
  • Average Net Cash Flow over 5 years is $762330.5, with a median of -$1.7 million recorded in 2023.
  • The sharpest move saw Net Cash Flow plummeted 309.89% in 2021, then soared 5664.22% in 2024.
  • Year by year, Net Cash Flow stood at -$3.7 million in 2021, then soared by 64.33% to -$1.3 million in 2022, then grew by 17.92% to -$1.1 million in 2023, then skyrocketed by 63.36% to -$398894.0 in 2024, then tumbled by 406.17% to -$2.0 million in 2025.
  • Business Quant data shows Net Cash Flow for SMTI at -$2.0 million in Q3 2025, -$3.7 million in Q2 2025, and $4.8 million in Q1 2025.